Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

maytansinoid conjugate

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (4) Antibody-Drug Conjugates (ADCs) (3) Antifolate (1) Bacterial (1) CCR (1) Checkpoint Kinase (Chk) (1) CXCR (1) Drug-Linker Conjugates for ADC (4) Microtubule/Tubulin (5) STAT (1)
By Research Areas:	Cancer (12)
Click Chemistry:	ADC Synthesis (2) DBCO (2)

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-136261

DM1-PEG4-DBCO	Drug-Linker Conjugates for ADC	Cancer
DM1-(PEG)4-DBCO is a agent-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody agent conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. DM1-PEG4-DBCO is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-148870

Maytansinoid B	ADC Cytotoxin	Cancer
Maytansinoid B is a kind of ADC Cytotoxin. Maytansinoid B can be used to conjugates with antibodies to form *antibody-drug conjugates* (ADCs)*. Maytansinoids* are known as antimitotic agents, binding to tubulin and inhibiting microtubule assembly. Maytansinoids induces G2/M arrest in the cell cycle to induce apoptosis .

HY-141606

Anetumab ravtansine BAY 94-9343	Microtubule/Tubulin Antibody-Drug Conjugates (ADCs)	Cancer
Anetumab ravtansine (BAY 94-9343) is a selective and highly potent antibody-drug conjugate (ADC) to target maytansinoid tubulin. Anetumab ravtansine consists of a human anti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine shows antitumor efficacy correlated with the amount of mesothelin expressed in patient-derived xenograft tumor models .

HY-19792

Mertansine 15+ Cited Publications DM1; maytansinoid DM1	Microtubule/Tubulin ADC Cytotoxin	Cancer
Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) .

HY-139441

DM21	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
DM21 is a next-generation linker-payload that combines a maytansinoid microtubule-disrupting payload with a stable tripeptide linker. DM21 is conjugated with a humanized antibody against ADAM9 to obtain IMGC936 .

HY-130080

DM3 maytansinoid DM3	ADC Cytotoxin Microtubule/Tubulin	Cancer
DM3 (Maytansinoid DM3), a Maytansine (HY-13674) analog bearing disulfide or thiol groups, and is a tubulin inhibitor. DM3 a cytotoxic moiety of antibody-drug conjugates (ADCs) .

HY-141607

Indatuximab ravtansine BT-062; nBT062-DM4	Antibody-Drug Conjugates (ADCs) Bacterial	Cancer
Indatuximab ravtansine (BT-062) is an *antibody-drug conjugate* (ADC) (Antibody-Drug Conjugates (ADCs)*) based on a murine/human chimeric form of B-B4 (specific for CD138), linked to the maytansinoid* agent DM4 by disulphide bonds. Indatuximab ravtansine shows anti-tumor activities .

HY-100128

DM1-SMe	Microtubule/Tubulin ADC Cytotoxin	Cancer
DM1-SMe is an unconjugated form of the Maytansinoid in IMGN901. DM1-SMe is the microtubule inhibitor and can be used as the ADC cytotoxin .

HY-151559

*Zn-DPA-maytansinoid* conjugate 1**	Checkpoint Kinase (Chk) STAT CXCR CCR	Cancer
Zn-DPA-maytansinoid conjugate 1 is a small molecule-based maytansinoid conjugate targeting immune checkpoint. Zn-DPA-maytansinoid conjugate 1 induces lasting regression of tumor growth and rejuvenates tumor microenvironment (TME) to an "inflamed hot tumor" .

HY-145663

HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM	Drug-Linker Conjugates for ADC	Cancer
HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM is a agent-linker (peptide-cleavable) conjugate for ADC. DM indicates the maytansinoid moiety .

HY-136260

DBCO-PEG4-Ahx-DM1	Drug-Linker Conjugates for ADC	Cancer
DBCO-PEG4-Ahx-DM1 is a agent-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody agent conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. DBCO-PEG4-Ahx-DM1 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-132258A

Mirvetuximab soravtansine (solution) 1 Publications Verification IMGN853 (solution)	Antibody-Drug Conjugates (ADCs) Antifolate	Cancer
Mirvetuximab soravtansine (IMGN853) solution is an anti-folate receptor α (FRα) antibody drug-conjugate (ADC) consisting of the cytotoxic maytansinoid, DM4, covalently linked to the humanized monoclonal antibody M9346A. Mirvetuximab soravtansine selectively binds to folate receptor 1 (FOLR1). Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage .

Cat. No.	Product Name

HY-L023

Toxins for Antibody-Drug Conjugate Research Library	113 compounds
Antibody-Drug Conjugates (ADCs), a new class of treatment for cancer, are composed with a monoclonal antibody, a linker and a cytotoxic agent also referred to as a payload. To date, several ADCs have received market approval and more than 60 ADCs are currently in clinical trials. ADCs are one of the fastest growing classes of oncology drugs worldwide. The payload or cytotoxic agent is the most important unit in the ADC. ADC has the capability to kill cancer cell depending on the potency of the payload. MCE provides 113 highly potent cytotoxins that contain auristatin derivatives, maytansinoids, calicheamicin, duocarmycin, pyrrolobenzodiazepines (PBDs), etc.

Toxins for Antibody-Drug Conjugate Research Library

113 compounds

Antibody-Drug Conjugates (ADCs), a new class of treatment for cancer, are composed with a monoclonal antibody, a linker and a cytotoxic agent also referred to as a payload. To date, several ADCs have received market approval and more than 60 ADCs are currently in clinical trials. ADCs are one of the fastest growing classes of oncology drugs worldwide.

The payload or cytotoxic agent is the most important unit in the ADC. ADC has the capability to kill cancer cell depending on the potency of the payload. MCE provides 113 highly potent cytotoxins that contain auristatin derivatives, maytansinoids, calicheamicin, duocarmycin, pyrrolobenzodiazepines (PBDs), etc.

Cat. No.	Product Name	Target	Research Area

HY-141606

Anetumab ravtansine BAY 94-9343	Microtubule/Tubulin Antibody-Drug Conjugates (ADCs)	Cancer
Anetumab ravtansine (BAY 94-9343) is a selective and highly potent antibody-drug conjugate (ADC) to target maytansinoid tubulin. Anetumab ravtansine consists of a human anti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine shows antitumor efficacy correlated with the amount of mesothelin expressed in patient-derived xenograft tumor models .

HY-141607

Indatuximab ravtansine BT-062; nBT062-DM4	Antibody-Drug Conjugates (ADCs) Bacterial	Cancer
Indatuximab ravtansine (BT-062) is an *antibody-drug conjugate* (ADC) (Antibody-Drug Conjugates (ADCs)*) based on a murine/human chimeric form of B-B4 (specific for CD138), linked to the maytansinoid* agent DM4 by disulphide bonds. Indatuximab ravtansine shows anti-tumor activities .

Cat. No.	Product Name		Classification

HY-136261

DM1-PEG4-DBCO		DBCO ADC Synthesis
DM1-(PEG)4-DBCO is a agent-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody agent conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. DM1-PEG4-DBCO is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-136260

DBCO-PEG4-Ahx-DM1		DBCO ADC Synthesis
DBCO-PEG4-Ahx-DM1 is a agent-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody agent conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. DBCO-PEG4-Ahx-DM1 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.